HRMY EV/EBITDA: current value, 10-year range and year-by-year history
Cash & Leverage
HRMY's ev/ebitda is lower than 65% of the last 10 years.
EV/EBITDA History
HRMY EV/EBITDA by year
Yearly range of HRMY’s ev/ebitda from 2020 to 2026. Over the full period it ranged from 3.9 to 86.8, averaging 19.6.
| Year | Low | Average | High | Year-end |
|---|---|---|---|---|
| 2026 | 4.2 | 6.3 | 7.7 | 6.8 |
| 2025 | 3.9 | 6.5 | 8.9 | 6.7 |
| 2024 | 6.2 | 7.6 | 9.8 | 7.4 |
| 2023 | 4.6 | 12.4 | 22.8 | 8.2 |
| 2022 | 27.2 | 38.8 | 56.3 | 34.0 |
| 2021 | 21.5 | 43.4 | 86.8 | 46.8 |
| 2020 | 77.6 | 77.6 | 77.6 | 77.6 |
Get notified when HRMY EV/EBITDA crosses a threshold
Free — one alert setup, notifications by push, Telegram, or Discord.
An acquisition-style valuation multiple: Enterprise Value (market cap + net debt) divided by operating earnings before accounting adjustments. Compares companies fairly regardless of their capital structure.
(Market Cap + Net Debt) / EBITDAUnlike P/E, this metric accounts for debt — two companies with identical operations but different leverage will show similar EV/EBITDA. Low vs history suggests the total business is modestly priced.
- EBITDA ignores capital expenditure. For asset-heavy businesses (airlines, mining, utilities), this understates the real cost — use EV/EBIT or EV/FCF instead.
- Large acquisitions temporarily spike net debt and can distort the ratio for 1–2 years during integration.
Is HRMY EV/EBITDA High or Low Right Now?
Harmony Biosciences Holdings, Inc.'s EV/EBITDA is currently 6.8, which is below average relative to its 10-year historical range. The 10-year median EV/EBITDA for HRMY is approximately 9.6. See all HRMY valuation metrics →
Unlock 10y, 15y, 20y, and 30y history with peer comparison and CSV export.